- Home
- STEC vs GBIO Comparison
STEC vs GBIO Comparison
Compare STEC & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- GBIO
- Stock Information
- Founded
- STEC 2006
- GBIO 2016
- Country
- STEC Hong Kong
- GBIO United States
- Employees
- STEC N/A
- GBIO N/A
- Industry
- STEC
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- GBIO Health Care
- Exchange
- STEC NYSE
- GBIO Nasdaq
- Market Cap
- STEC 63.8M
- GBIO 29.5M
- IPO Year
- STEC 2021
- GBIO 2020
- Fundamental
- Price
- STEC $0.74
- GBIO $4.39
- Analyst Decision
- STEC
- GBIO Strong Buy
- Analyst Count
- STEC 0
- GBIO 4
- Target Price
- STEC N/A
- GBIO $73.33
- AVG Volume (30 Days)
- STEC 12.8K
- GBIO 210.2K
- Earning Date
- STEC 08-05-2025
- GBIO 08-06-2025
- Dividend Yield
- STEC N/A
- GBIO N/A
- EPS Growth
- STEC N/A
- GBIO N/A
- EPS
- STEC N/A
- GBIO N/A
- Revenue
- STEC $10,672,000.00
- GBIO $24,556,000.00
- Revenue This Year
- STEC $9,392.20
- GBIO N/A
- Revenue Next Year
- STEC N/A
- GBIO N/A
- P/E Ratio
- STEC N/A
- GBIO N/A
- Revenue Growth
- STEC N/A
- GBIO 146.47
- 52 Week Low
- STEC $0.20
- GBIO $3.00
- 52 Week High
- STEC $3.25
- GBIO $35.80
- Technical
- Relative Strength Index (RSI)
- STEC 38.03
- GBIO 53.21
- Support Level
- STEC $0.70
- GBIO $4.28
- Resistance Level
- STEC $0.80
- GBIO $5.10
- Average True Range (ATR)
- STEC 0.08
- GBIO 0.62
- MACD
- STEC 0.00
- GBIO 0.01
- Stochastic Oscillator
- STEC 34.03
- GBIO 30.16
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a technology company focusing on exploring various opportunities in consumer technology, consumer healthcare and enterprise technology. It has two revenue segments Wealth management service and Asset management service. Key revenue is generated from Wealth management service.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.